Continuous subcutaneous insulin infusion (CSII) devices are designed to provide physiologic insulinemia. Not only do they offer increased life-style flexi bility, they also make it possible to achieve near-normal levels of glycemia. These devices are programmed to deliver a continuous "basal" infusion. Preprandial bolus doses of insulin are given to prevent postprandial hyperglycemia. Careful patient screening and selection are necessary to ensure a successful outcome. Patients must have the maturity, technical ability, motivation, and financial resources needed to utilize CSII therapy. Initiation of CSII can be accomplished in an outpatient or inpatient setting, but both require a comprehensive educational curriculum.
Get full access to this article
View all access options for this article.
References
1.
Santiago JV, White NH, Skor DAMechanical devices for insulin delivery. In: Nattrass M, Santiago JV, eds. Recent advances in diabetes. Edinburgh: Churchill Livingstone, 1984:145-63.
2.
White NH, Santiago JVWhat can be achieved with and what are the complications of the insulin pump ? In: L'Etang HJC, ed. Diabetes mellitus: achievements and scepticism. London : Royal Society of Medicine, 1984 :111-25.
3.
American Association of Diabetes Educators.Education for continuous subcutaneous insulin infusion pump users [Position Statement]. Diabetes Educ1987;13:10.
4.
American Diabetes Association.Continuous subcutaneous insulin infusion [Policy Statement]. Diabetes Care1985;8:516-17.
5.
Schade DS, Santiago JV, Skyler JS, Rizza RASelection and management of the patient receiving intensive insulin therapy. In: Intensive insulin therapy. Princeton: Excerpta Medica, 1983;194-208.
6.
Weinrauch S. , Tomky D.Commonly asked questions about pump therapy . Diabetes Educ1983;9(1):30-31.
7.
Jornsay DL, Duckles AE, Hankinson JPPsychological considerations for patient selection and adjustment to insulin pump therapy. Diabetes Educ1988 ;14:291-96.
8.
Fredrickson F.Patient selection. In: Modem insulin pump therapy: a guide for successful implementation. Sylmar, California: MiniMed Technologies, 1987:6-8.
9.
Santiago JV, Clemens AH, Clarke WL, Kipnis DMClosed-loop and open-loop devices for blood glucose control in normal and diabetic subjects. Diabetes1979;28:71-84.
10.
Schade DS, Santiago JV, Skyler JS, Rizza RAInsulin-infusion devices: current hardware and future expectations. In: Intensive insulin therapy. Princeton: Excerpta Medica, 1983:317-34.
11.
Tomky D., Weinrauch S.1987 buying guide to diabetes supplies. Diabetes Forecast1987;40:31-45.
12.
Mecklenburg RS, Guinn TS, Sannar CA, Blumenstein BAMalfunction of continuous subcutaneous insulin infusion systems: a one-year prospective study of 127 patients. Diabetes Care1986 ;9:351-55.
13.
D'Agostino M., Bucholtz JF, Pelle A., Robins B., Bucholtz HKInitiation of insulin pump therapy in the ambulatory setting. Diabetes Educ1983;9(1):35-37.
14.
White NH, Skor DA, Santiago JVPractical closed-loop insulin delivery. A system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin dependent diabetes. Ann Intern Med1982;97:210-13.
15.
Skyler JS, Seigler DE, Reeves MLA comparison of insulin regimens in insulin-dependent diabetes mellitus . Diabetes Care1982;5(suppl 1): 11-18.
Sherwin RS, Tamborlane WV, Genel M., Felig P.Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump. Diabetes Care1980;3:301-8.
18.
Clark WL, Haymond MW, Santiago JVOvernight basal insulin requirements in fasting insulin dependent diabetics . Diabetes1980;29:778-80.
19.
Nestler JE, Gebhart Ssp, Blackard WGFailure of a nocturnal insulin infusion to suppress the increased insulin need for breakfast in insulin-dependent diabetic patients. Diabetes1984;33:266-70.
20.
Grinvalsky M., Nathan DMDiets for insulin pump and multiple daily injection therapy. Diabetes Care1983 ;6:241-44.
21.
Chantelau E. , Sonnenberg GE, Stanitzek-Schmidt I., Best F., Altenhr H., Berger M.Diet liberalization and metabolic control in type I diabetic outpatients treated by continuous subcutaneous insulin infusion. Diabetes Care1982;5:612-16.
22.
Hildebrandt P., Birch K., Jensen BM, Kuhl C.Subcutaneous insulin infusion change in basal rate has no immediate effect on insulin absorption rate. Diabetes Care1986;9:561-64.
23.
Kraegen EW, Chisholm DJ, McNamara ME. Timing of insulin delivery with meals. Horm Metab Res1981;13:365-67.
24.
Witt MF, White NH, Santiago JVRoles of site and timing of the morning insulin injection in type I diabetes . J Pediatr1983; 103:528-33.
25.
Dimitriadis GD, Gerich JEImportance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus . Diabetes Care1983;6:374-77.
26.
White NH, Waltman SR, Krupin T., Santiago JVReversal of abnormalities in ocular fluorophotometry in insulin-dependent diabetes after five to nine months of improved metabolic control. Diabetes1982;31:80-85.
27.
Marliss EB, Caron D., Albisser AM, Zinman B.Present and future expectations regarding insulin infusion systems . Diabetes Care1981;4:325-26.
28.
Santiago JV , White NHStatus of pancreatic transplants and mechanical devices for blood glucose controls in diabetes. Ann Biomed Eng1980;8:525-38.
29.
Schade DS, Eaton RP, Carlson GA, et al. Future therapy of the insulin-dependent diabetic patient—the implantable insulin delivery system. Diabetes Care1981 ;4:319-24.
30.
Buchwald H. , Rohde TD, Dorman FD, et al. A totally implantable drug infusion device: laboratory and clinical experience using a model with single flow rate and new design for modulated insulin infusion. Diabetes Care1980;3:351-58.
31.
Schade DS, Eaton RPThe peritoneum—a potential insulin delivery route for a mechanical pancreas . Diabetes Care1980;3:229-34.
